Capecitabine + Carboplatin + Cisplatin + Sacituzumab govitecan
Phase 3Active 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-negative Breast Cancer
Conditions
HER2-negative Breast Cancer, Triple Negative Breast Cancer
Trial Timeline
Oct 28, 2020 → Mar 30, 2029
NCT ID
NCT04595565About Capecitabine + Carboplatin + Cisplatin + Sacituzumab govitecan
Capecitabine + Carboplatin + Cisplatin + Sacituzumab govitecan is a phase 3 stage product being developed by Gilead Sciences for HER2-negative Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04595565. Target conditions include HER2-negative Breast Cancer, Triple Negative Breast Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04595565 | Phase 3 | Active |
Competing Products
19 competing products in HER2-negative Breast Cancer